(Fighting against New Coronary Pneumonia) The number of people diagnosed in Germany has exceeded 204,000 volunteers to register for the vaccine test
China News Agency, Berlin, July 13 (Reporter Peng Dawei) As of the evening of the 12th local time, the cumulative number of people diagnosed with new coronary pneumonia in Germany has exceeded 200,000. German media quoted the information released by the University Hospital of Tübingen that day, and said that its new crown vaccine test started in mid-June has recruited about 4,000 volunteers, and the subjects have not yet experienced any unexpected adverse reactions.
According to the German "Times Online" report, as of 22 o'clock local time on the 12th, Germany accumulatively diagnosed 200106 people, cured 184622 people and died 9235 people.
Data Map: On July 3 local time, people pass by the Bremen City Hall, which is listed as a World Heritage Site. China News Service reporter Peng Dawei
While the epidemic has stabilized, Germany is accelerating the vaccine development process. The German "Daily News" website quoted on the 12th the news released by the University Hospital of Tübingen, Germany, showing that the hospital and the Tübingen-based vaccine company Curevac have launched a vaccine test project in cooperation with about 4,000 people since the middle of June. Volunteers who want to participate in the test.
Peter Kremsner, the head of the New Crown Vaccine Test Project at the University of Tübingen, told Deutsche Presse that unlike other clinical research projects that have to strive for subjects, the registration status of the New Crown Vaccine Test Project is "luxury" ". However, he also pointed out that most of the applicants will not be really vaccinated with the vaccine currently in the testing stage-according to the study design, the number of subjects who will be vaccinated is only 168. At present, nearly 50 people have been tested for vaccines, and "no unintended adverse reactions have occurred."
It is reported that Tübingen University Hospital is currently conducting the first phase of clinical trials of the new crown vaccine. If this stage is successful, the size of the subjects covered by the next clinical trials will be significantly expanded. (Finish)